Salvatore Calanna

5.9k total citations · 1 hit paper
27 papers, 4.0k citations indexed

About

Salvatore Calanna is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Salvatore Calanna has authored 27 papers receiving a total of 4.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Endocrinology, Diabetes and Metabolism, 11 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Salvatore Calanna's work include Diabetes Treatment and Management (17 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (10 papers). Salvatore Calanna is often cited by papers focused on Diabetes Treatment and Management (17 papers), Metabolism, Diabetes, and Cancer (11 papers) and Diabetes Management and Research (10 papers). Salvatore Calanna collaborates with scholars based in Denmark, Italy and United States. Salvatore Calanna's co-authors include Sean Wharton, Ildiko Lingvay, Thomas A. Wadden, Melanie J. Davies, Robert F. Kushner, John Wilding, Julio Rosenstock, Marie Thi Dao Tran, Barbara McGowan and Niels Zeuthen and has published in prestigious journals such as New England Journal of Medicine, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Salvatore Calanna

27 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Once-Weekly Semaglutide in Adults with Overweight or Obesity

2021 2.5k citations John Wilding, Rachel L. Batterham et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Salvatore Calanna Denmark	20	2.6k	1.3k	1.1k	1.0k	1.0k	27	4.0k
Zvonko Miličević United States	26	3.7k 1.4×	1.3k 0.9×	1.6k 1.5×	1.2k 1.1×	938 0.9×	83	4.5k
Sue D. Pedersen Canada	21	3.0k 1.1×	1.5k 1.1×	1.3k 1.2×	980 0.9×	1.0k 1.0×	49	4.2k
Xuewei Cui United States	16	2.9k 1.1×	1.2k 0.9×	1.5k 1.3×	1.1k 1.0×	865 0.9×	37	3.8k
Christine B. Jensen Denmark	22	2.5k 1.0×	1.8k 1.4×	1.2k 1.1×	898 0.9×	1.5k 1.5×	26	4.2k
Laura Fernández Landó United States	18	2.6k 1.0×	990 0.7×	1.1k 1.0×	754 0.7×	763 0.8×	52	3.2k
Niels Zeuthen Denmark	6	1.6k 0.6×	1.1k 0.8×	655 0.6×	626 0.6×	811 0.8×	17	2.7k
Adam Stefański United States	18	1.5k 0.6×	932 0.7×	554 0.5×	561 0.5×	883 0.9×	64	2.9k
Paula M. Hale United States	19	3.4k 1.3×	1.4k 1.1×	1.6k 1.4×	1.2k 1.2×	708 0.7×	43	4.2k
Marie Thi Dao Tran Denmark	6	1.5k 0.6×	1.0k 0.8×	599 0.5×	597 0.6×	792 0.8×	11	2.6k
Mathijs C. Bunck United States	10	1.6k 0.6×	1.0k 0.8×	458 0.4×	578 0.6×	968 1.0×	21	2.7k

Countries citing papers authored by Salvatore Calanna

Since Specialization

Citations

This map shows the geographic impact of Salvatore Calanna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salvatore Calanna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salvatore Calanna more than expected).

Fields of papers citing papers by Salvatore Calanna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salvatore Calanna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salvatore Calanna. The network helps show where Salvatore Calanna may publish in the future.

Co-authorship network of co-authors of Salvatore Calanna

This figure shows the co-authorship network connecting the top 25 collaborators of Salvatore Calanna. A scholar is included among the top collaborators of Salvatore Calanna based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salvatore Calanna. Salvatore Calanna is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wilding, John, Rachel L. Batterham, Salvatore Calanna, et al.. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 384(11). 989–1002. 2476 indexed citations breakdown →

Wilding, John, Rachel L. Batterham, Salvatore Calanna, et al.. (2021). Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). Journal of the Endocrine Society. 5(Supplement_1). A10–A10. 2 indexed citations

Calanna, Salvatore, et al.. (2021). 648-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Induces Lipolysis during Stable Basal Insulin Substitution and Hyperglycemia in Men with Type 1 Diabetes. Diabetes. 70(Supplement_1). 1 indexed citations

Calanna, Salvatore, et al.. (2021). Glucose‐dependent insulinotropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double‐blind, placebo‐controlled, crossover clinical trial. Diabetes Obesity and Metabolism. 24(1). 142–147. 8 indexed citations

Harrison, Stephen A., Salvatore Calanna, Kenneth Cusi, et al.. (2020). Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. Contemporary Clinical Trials. 97. 106174–106174. 34 indexed citations

Kushner, Robert F., Salvatore Calanna, Melanie J. Davies, et al.. (2020). Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 28(6). 1050–1061. 200 indexed citations

Newsome, Philip N., Sven Francque, Stephen A. Harrison, et al.. (2019). Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Alimentary Pharmacology & Therapeutics. 50(2). 193–203. 144 indexed citations

Nauck, Michael A., et al.. (2018). Neoplasms Reported With Liraglutide or Placebo in People With Type 2 Diabetes: Results From the LEADER Randomized Trial. Diabetes Care. 41(8). 1663–1671. 71 indexed citations

Zinman, Bernard, Steven P. Marso, Erik Christiansen, et al.. (2018). Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care. 41(8). 1783–1791. 71 indexed citations

10.

Leiter, Lawrence A., Bernard Zinman, Steven P. Marso, et al.. (2017). Severe Hypoglycemia, Cardiovascular Outcomes and Death in LEADER. Canadian Journal of Diabetes. 41(5). S68–S68. 1 indexed citations

11.

Privitera, G., L. Spadaro, C. Alagona, et al.. (2015). Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components. Acta Diabetologica. 53(3). 449–459. 16 indexed citations

12.

Piro, Salvatore, Loriana Mascali, Francesca Urbano, et al.. (2014). Chronic Exposure to GLP-1 Increases GLP-1 Synthesis and Release in a Pancreatic Alpha Cell Line (α-TC1): Evidence of a Direct Effect of GLP-1 on Pancreatic Alpha Cells. PLoS ONE. 9(2). e90093–e90093. 26 indexed citations

13.

Calanna, Salvatore, Roberto Scicali, Antonino Di Pino, et al.. (2014). Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutrition Metabolism and Cardiovascular Diseases. 24(6). 670–676. 29 indexed citations

14.

Calanna, Salvatore, Roberto Scicali, Antonino Di Pino, et al.. (2014). Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Acta Diabetologica. 51(4). 567–575. 30 indexed citations

15.

Pino, Antonino Di, Roberto Scicali, Salvatore Calanna, et al.. (2014). Cardiovascular Risk Profile in Subjects With Prediabetes and New-Onset Type 2 Diabetes Identified by HbA1c According to American Diabetes Association Criteria. Diabetes Care. 37(5). 1447–1453. 53 indexed citations

16.

Calanna, Salvatore, Salvatore Piro, Antonino Di Pino, et al.. (2013). Beta and alpha cell function in metabolically healthy but obese subjects: Relationship with entero‐insular axis. Obesity. 21(2). 320–325. 28 indexed citations

17.

Calanna, Salvatore, Mikkel Christensen, Jens J. Holst, et al.. (2013). Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia. 56(5). 965–972. 194 indexed citations

18.

Calanna, Salvatore, Francesca Urbano, Salvatore Piro, et al.. (2012). Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome. European Journal of Endocrinology. 166(5). 917–922. 24 indexed citations

19.

Pino, Antonino Di, C. Alagona, Salvatore Piro, et al.. (2012). Separate impact of metabolic syndrome and altered glucose tolerance on early markers of vascular injuries. Atherosclerosis. 223(2). 458–462. 30 indexed citations

20.

Spadaro, L., C. Alagona, Filippo Palermo, et al.. (2010). Early phase insulin secretion is increased in subjects with normal fasting glucose and metabolic syndrome: a premature feature of beta-cell dysfunction. Nutrition Metabolism and Cardiovascular Diseases. 21(3). 206–212. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact